Full-Time

Executive Assistant

Posted on 12/29/2024

Tarsus Pharamceuticals

Tarsus Pharamceuticals

201-500 employees

Develops treatments for eye care diseases

Compensation Overview

$86.2k - $120.8k/yr

+ Bonus + Stock Equity

Senior, Expert

Irvine, CA, USA

This position is hybrid, requiring some in-office presence.

Category
Executive Support
Administrative & Executive Assistance
Requirements
  • Minimum High School diploma/GED or 4 years of equivalent experience in a professional business-oriented industry. Bachelor’s degree preferred.
  • Minimum 13 years administrative experience or 5+ years with Bachelor’s, with at least 3 years supporting senior level executives.
  • Demonstrated ability to develop and maintain strong working partnerships.
  • Well organized and efficient with handling multiple tasks simultaneously.
  • Excellent time management skills and ability to prioritize work and activities with limited guidance while able to meet stringent deadlines.
  • Able to provide clear guidance and direction for other support team members.
  • Proactive thinker – creative and consistently generate new and original ideas to improve processes and procedures.
  • Must understand, follow, and comply with regulatory requirements as applicable to various processes.
  • Must possess a thorough understanding of common business practices and work-related standards and regulations, including but not limited to Standard Operating Procedures (SOPs).
  • Excellent verbal and written communication skills.
  • Proficient with Microsoft Office Suite and various computer programs that will offer improved productivity for the position.
  • Proficient in scheduling travel, meetings, and coordination for the executives.
  • Strong problem-solving, judgment and decision-making skills are required.
Responsibilities
  • Prepare or generate documents including routine internal and external correspondence and communication, timelines, charts, tables, meeting agendas, minutes, and presentations in organized and visually appealing style.
  • Coordinate arrangements for executive meetings including travel and lodging needs; including international travel.
  • Ability to maintain confidentiality and high-level information. Set-up and maintain records and files, which may contain confidential information.
  • Maintain executive calendar and perform daily scheduling.
  • Handle special projects in an independent approach; participate in cross-functional teams as member or leader.
  • Support departmental team members with Microsoft Office Suite functions.
  • Enter expense reports according to Travel & Expense Policy.
  • Provide back-up phone assistance when needed.
  • Coordinate logistics and catering for corporate meetings and conferences as needed.
  • Plan and coordinate corporate events throughout the year. Includes all planning, vendor selection, vendor contract negotiation, creating task force committees, event execution and follow-up.
  • Use problem analysis and project management skills to complete special projects as requested.
Desired Qualifications
  • Bachelor’s degree preferred.
Tarsus Pharamceuticals

Tarsus Pharamceuticals

View

Tarsus Pharmaceuticals develops treatments for diseases that lack effective solutions, focusing mainly on eye care and infectious diseases. Their key product, XDEMVY, is an FDA-approved eye drop solution used to treat Demodex Blepharitis, a condition affecting the eyelids. Tarsus's products work by targeting specific medical conditions, and they have a pipeline of potential treatments for Lyme Disease Prevention, Meibomian Gland Disease, and Rosacea. What sets Tarsus apart from competitors is their commitment to addressing high unmet medical needs and their strategic partnerships that enhance their research capabilities. The company's goal is to provide effective treatments for patients suffering from these conditions while ensuring compliance with regulations and ethical standards.

Company Size

201-500

Company Stage

IPO

Headquarters

Irvine, California

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarsus secured $200 million in non-dilutive financing from Pharmakon Advisors in April 2024.
  • The rise of telemedicine offers Tarsus new channels to reach patients directly.
  • Increasing global prevalence of eye diseases boosts demand for Tarsus's ophthalmic products.

What critics are saying

  • Increased competition in ophthalmic treatments could impact Tarsus's market share.
  • Potential regulatory changes may delay Tarsus's clinical trials and product launches.
  • Rising raw material costs could affect the profitability of Tarsus's products.

What makes Tarsus Pharamceuticals unique

  • Tarsus focuses on high unmet needs in ophthalmic and infectious diseases.
  • Their lead product, TP-03, targets Demodex blepharitis, a condition with limited treatments.
  • Tarsus's FDA-approved XDEMVY offers a novel solution for Demodex blepharitis.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Hybrid Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

7%
GlobeNewswire
Mar 13th, 2025
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of...

MarketBeat
Nov 22nd, 2024
Mutual of America Capital Management LLC Invests $4.29 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Mutual of America Capital Management LLC invests $4.29 million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS).

The Manila Times
Nov 13th, 2024
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

Tarsus welcomes Kate Goodrich, M.D., MHS, to its Board of Directors.

Vision Monday
Nov 12th, 2024
Tarsus Pharmaceuticals Appoints Elizabeth Yeu, MD, as Chief Medical Officer

IRVINE, Calif.- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a company that applies proven science and new technology to eyecare to improve treatment for patients, has announced the appointment of Elizabeth Yeu, MD, as chief medical officer, effective November 4, 2024.

Fierce Pharma
Aug 14th, 2024
Tarsus 'firing on all cylinders' as Xdemvy launch, sales force expansion roll ahead: CEO

Meanwhile, Tarsus in April picked up $200 million in financing from Pharmakon Advisors, on top of the $180 million equity offering the company pulled off earlier in the year.

INACTIVE